Physician profile

Anna White

Internal Medicine · Dallas, TX

NPI 1740930825

$204.56

in general payments reported to CMS, 2019-2025

4 companies · $205 in 2025

The $205 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$204.56

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $121.84 2025
Lilly USA, LLC $39.65 2025 Jardiance
Novo Nordisk INC $28.73 2025 Ozempic
Amgen INC. $14.34 2025 Repatha

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anna White

$204.56

in general payments reported 2019-2025

Years
2025
Top company
Bayer Healthcare Pharmaceuticals INC.
Context
The $205 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/11947816/anna-white

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.